WASHINGTON, DC--(Marketwired - January 30, 2014) - The Alliance for Regenerative Medicine (ARM) today announced its second annual Regen Med Investor Day, in partnership with top financial firms Maxim Group and Piper Jaffray. This one-day meeting is the only investment conference designed specifically to provide institutional investors and life science analysts with insight into key value drivers at the leading small- and mid- cap regenerative medicine and advanced therapy companies. The meeting will be held March 26, 2014 beginning at 8:00 am at the Metropolitan Club, New York, NY.
This high-impact program will include dynamic discussions between key opinion leaders, top analysts and senior executives regarding the latest information on the industry's prominent disease indications. Additionally, up to 32 of the field's most promising companies from across the globe, both public and private, will give focused presentations.
Silviu Itescu, CEO and Managing Director of Mesoblast, will provide the lunch keynote presentation. The event will also feature a high-level discussion between Perry Karsen, CEO of Celgene Cellular Therapeutics and EVP and COO of Celgene Corporation and Eric Roman, General Manager of Research and Applied Markets at GE Healthcare Life Sciences. This "fireside chat" which kicks off the program will highlight how the sector is distinctively positioned to accelerate commercialization for both tool and therapeutic-focused companies.
"During the last 100 years, medical innovation increased life expectancy by more than 60% and decreased mortality by over 90%," said Perry Karsen. "Medical innovators, like Celgene, have continued that success into the 21st century with life-enhancing therapies accounting for more than 70% of the increase in life expectancy. That said, pro-innovation and pro-patient policies will be the vital spark that sustains investment opportunities in the field of regenerative medicine that holds the potential of even greater promise for patients, healthcare and our economy."
The initial slate of presenting companies includes: Athersys, BioTime, Capricor, Cytori Therapeutics, Fibrocell Science, Harvard Apparatus Regenerative Technology, ISTO Technologies, Juventas Therapeutics, Mesoblast, MiMedx, NeoStem, Pluristem Therapeutics, Organovo, Oxford BioMedica, Prima BioMed, ReNeuron, Sangamo BioSciences, StemCells, Inc. and TiGenix.
Co-hosts for the event include Piper Jaffray and Maxim Group. The meeting is also sponsored by NeoStem and Progenitor Cell Therapy (PCT). Further details of the agenda and presenting companies will be released in coming weeks. For more information visit the event's website at http://arminvestorday.com/. Credentialed investors, life science strategic partners and members of the media should contact Laura Parsons at firstname.lastname@example.org if interested in attending.
About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, DC to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 150 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit www.alliancerm.org.